News

FDA approves tofersen, now Qalsody, as treatment for SOD1-ALS

The U.S. Food and Drug Administration (FDA) has granted conditional approval to Biogen’s tofersen, now named Qalsody, for the treatment of amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene. The decision, which marks the first conditional approval for ALS in the country, comes about eight…

Pison’s AI-powered technology may help identify early ALS

A new technology powered by artificial intelligence (AI) may one day help doctors diagnose people in the early stages of amyotrophic lateral sclerosis (ALS), according to data from a clinical trial. Developed by Pison, the technology was able to detect involuntary muscle twitches, or fasciculations, and changes in…

Second ALS treatment center of excellence opens in New Jersey

A certified care center of excellence for amyotrophic lateral sclerosis (ALS) has opened in Hackensack Meridian Neuroscience Institute at the Jersey Shore University Medical Center. The ALS Center is part of the medical center’s Dr. Robert H. Harris Neuroscience Treatment Center in Neptune, New Jersey. “Our multidisciplinary…

AIT-101 clears toxic protein clumps, early data show

AI Therapeutics‘ experimental therapy AIT-101 led to reductions in levels of toxic proteins in people with amyotrophic lateral sclerosis (ALS) associated with mutations in the C9ORF72 gene, according to data from a clinical trial. The Phase 2a clinical trial also met its main goals of showing that AIT-101…